Pipeline Overview

Armata’s therapeutic phage candidates aim to address areas of significant unmet clinical need, by targeting key antibiotic-resistant bacteria including those on the World Health Organization’s global priority pathogens list. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Proprietary synthetic phage candidates designed to target an undisclosed infectious disease agent are being developed in partnership with Merck. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing.

Pathogen / Indication	Discovery	Preclinical	IND-Enabling	CMC	Phase 1b/2
Pseudomonas aeruginosa Cystic Fibrosis Lung Infections	AP-PA02
Staphylococcus aureus Bacteremia	AP-SA02
Undisclosed	Partnered

Phage Candidate	Pathogen & Indication	Phase	Partner
AP-PA02	P. aeruginosa CF Lung Infection	Phase 1/2 (1H20)
AP-SA02	S. aureus Bacteremia	Phase 1/2 (2H20)
	Undisclosed	Discovery